Oteseconazole (VT-1161; Vivjoa) is a novel, oral and potent tetrazole-based antifungal agent with the potential to be used for the treatment of candidal vaginal infection. VT-1161 binds to and inhibits Candida albicans CYP51 with a Kd of <39 nM. It protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection. As of April 2022, The FDA has approved osteseconazole (Vivjoa) capsules for the treatment of recurrent vulvovaginal candidiasis (RVVC), also known as chronic yeast infection, in women with a history of the condition who are not of reproductive potential. The azole antifungal is the first and only FDA-approved treatment for RVVC, and showing sustained efficacy in significant long-term reduction of recurrence of the condition through 50 weeks compared with comparators, according to Mycovia Pharmaceuticals.

纯度：≥98%

CAS：1340593-59-0